Lymphoma, Non-Hodgkin Clinical Trials

34 recruitingLast updated: June 17, 2026

There are 34 actively recruiting lymphoma, non-hodgkin clinical trials across 21 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4. Top locations include New York, New York, United States, Houston, Texas, United States, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


Lymphoma, Non-Hodgkin Trials at a Glance

34 actively recruiting trials for lymphoma, non-hodgkin are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 1 with 15 trials, with the heaviest enrollment activity in New York, Houston, and Nashville. Lead sponsors running lymphoma, non-hodgkin studies include National Cancer Institute (NCI), Janssen Research & Development, LLC, and Eli Lilly and Company.

Browse lymphoma, non-hodgkin trials by phase

Treatments under study

About Lymphoma, Non-Hodgkin Clinical Trials

Looking for clinical trials for Lymphoma, Non-Hodgkin? There are currently 30 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lymphoma, Non-Hodgkin trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lymphoma, Non-Hodgkin clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 34 trials

Recruiting
Phase 1Phase 2

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Merck Sharp & Dohme LLC200 enrolled4 locationsNCT07519772
Recruiting
Phase 1Phase 2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Acute Lymphoblastic LeukemiaLymphoma, Non-HodgkinB-cell Lymphoma+8 more
National Cancer Institute (NCI)130 enrolled1 locationNCT05442515
Recruiting
Phase 2

Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation

Chronic Lymphocytic LeukemiaHodgkin LymphomaMyeloma+4 more
University Hospital, Clermont-Ferrand150 enrolled20 locationsNCT04935684
Recruiting
Phase 1Phase 2

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC439 enrolled32 locationsNCT05421663
Recruiting

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Non-small Cell Lung CancerMultiple MyelomaLymphoma, Non-Hodgkin+2 more
National Cancer Institute (NCI)500 enrolled1 locationNCT02682667
Recruiting
Phase 1

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

Lymphoma, Non-Hodgkin
Janssen Research & Development, LLC130 enrolled9 locationsNCT07308132
Recruiting
Phase 1

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Follicular LymphomaLymphoma Diffuse Large B-cellLymphoma, Non-Hodgkin's
Eli Lilly and Company460 enrolled46 locationsNCT07226843
Recruiting
Phase 2

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid Leukemia+4 more
University of Florida20 enrolled1 locationNCT05800210
Recruiting
Phase 4

Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

Lymphoma, Non-HodgkinStreptococcus PneumoniaeVaccine
Poitiers University Hospital160 enrolled7 locationsNCT04460235
Recruiting
Phase 2

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled181 locationsNCT02693535
Recruiting
Phase 1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Lymphoma, B-CellChronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)+1 more
Umoja Biopharma106 enrolled8 locationsNCT06528301
Recruiting
Phase 2

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

High-grade B-cell LymphomaLymphoma, Non-HodgkinRefractory Diffuse Large B-Cell Lymphoma+2 more
Abramson Cancer Center at Penn Medicine31 enrolled1 locationNCT06458439
Recruiting

Tissue Collection for Studies of Lymph Cancer

Multiple MyelomaLymphoma, Non-HodgkinLeukemia-Lymphoma, Adult T-Cell+2 more
National Cancer Institute (NCI)1,295 enrolled2 locationsNCT01676805
Recruiting

AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients.

Lymphoma, Non-HodgkinCare Coordination
Grand Hôpital de Charleroi210 enrolled1 locationNCT07546188
Recruiting
Not Applicable

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

LymphomaSedentary BehaviorLymphoma, Non-Hodgkin+1 more
Dana-Farber Cancer Institute24 enrolled1 locationNCT06923397
Recruiting
Phase 1

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

LymphomaLymphoma, Non-Hodgkin
Treeline Biosciences, Inc.180 enrolled12 locationsNCT07082803
Recruiting
Phase 2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
Canadian Cancer Trials Group720 enrolled10 locationsNCT03297606
Recruiting
Phase 2

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

LymphomaLymphoma, Non-HodgkinFollicular Lymphoma+1 more
Beth Israel Deaconess Medical Center35 enrolled3 locationsNCT06510361
Recruiting
Phase 2

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Lymphoma, Non-HodgkinB-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Eli Lilly and Company13 enrolled6 locationsNCT07162181
Recruiting
Phase 1

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Triple-Negative Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Cancer+11 more
OncoNano Medicine, Inc.168 enrolled16 locationsNCT06022029